Bausch Health Companies (BHC)
NYSE:BHC
BHC Stock Chart & Stats
$5.90
-$0.02(-0.25%)
At close: 4:00 PM EST
$5.90
-$0.02(-0.25%)
Day’s Range― - ―
52-Week Range$4.93 - $8.69
Previous Close$7.83
Volume991.97K
Average Volume (3M)2.02M
Market Cap
$1.92B
Enterprise Value$21.50B
Total Cash (Recent Filing)$1.30B
Total Debt (Recent Filing)$20.80B
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Aug 05, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.21
Shares Outstanding373,475,650
10 Day Avg. Volume2,212,884
30 Day Avg. Volume2,020,349
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-4.65
Price to Sales (P/S)0.25
P/FCF Ratio2.64
Enterprise Value/Market Cap11.17
Enterprise Value/Revenue2.45
Enterprise Value/Gross Profit3.23
Enterprise Value/Ebitda4.09
Forecast
1Y Price Target
$7.67Price Target Upside29.94% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)4.28
Revenue Forecast (FY)$10.55B
Bulls Say, Bears Say
Bulls Say
Company GuidanceCompany guidance exceeded prior analyst estimates, implying management expects stronger top-line growth than the market had anticipated.
Pipeline Opportunity — LarsucosterolInvestor focus on larsucosterol as a potential first approved treatment for severe alcohol-associated hepatitis could create a meaningful new commercial opportunity if regulatory approval is achieved.
Revenue And Product MixTotal revenue surpassed analysts' expectations driven by stronger vision-care sales, indicating diversification of revenue sources beyond core pharmaceuticals.
Bears Say
Clinical Trial SetbackPhase three RED-C program failing to meet its primary endpoint undermines prospects for the rifaximin asset and reduces expected contribution from new formulations.
Loss Of Exclusivity RiskLoss of exclusivity for Xifaxan represents a major revenue overhang that could materially reduce future sales without an immediate replacement product.
Profitability And Deal-making ConstraintsHigher selling and administrative expenses together with elevated interest costs and limited capital flexibility constrain the company's ability to pursue large business development deals and put pressure on profitability.
Bausch Health Companies News
BHC FAQ
What was Bausch Health Companies’s price range in the past 12 months?
Bausch Health Companies lowest stock price was $4.93 and its highest was $8.69 in the past 12 months.
What is Bausch Health Companies’s market cap?
Bausch Health Companies’s market cap is $1.92B.
When is Bausch Health Companies’s upcoming earnings report date?
Bausch Health Companies’s upcoming earnings report date is Aug 05, 2026 which is in 55 days.
How were Bausch Health Companies’s earnings last quarter?
Bausch Health Companies released its earnings results on Apr 29, 2026. The company reported $0.767 earnings per share for the quarter, beating the consensus estimate of $0.664 by $0.103.
Is Bausch Health Companies overvalued?
According to Wall Street analysts Bausch Health Companies’s price is currently Undervalued.
Does Bausch Health Companies pay dividends?
Bausch Health Companies pays a Quarterly dividend of $1 which represents an annual dividend yield of N/A. See more information on Bausch Health Companies dividends here
What is Bausch Health Companies’s EPS estimate?
Bausch Health Companies’s EPS estimate is 1.
How many shares outstanding does Bausch Health Companies have?
Bausch Health Companies has 373,475,650 shares outstanding.
What happened to Bausch Health Companies’s price movement after its last earnings report?
Bausch Health Companies reported an EPS of $0.767 in its last earnings report, beating expectations of $0.664. Following the earnings report the stock price went up 2.326%.
Which hedge fund is a major shareholder of Bausch Health Companies?
Currently, no hedge funds are holding shares in BHC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bausch Health Companies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$7.67 (29.94% Upside)
$7.67 (29.94% Upside)
Blogger Sentiment
Bullish
BHC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.37%
12-Months-Change
Fundamentals
Return on Equity
120.75%
Trailing 12-Months
Asset Growth
-7.28%
Trailing 12-Months
Company Description
Bausch Health Companies
Bausch Health Companies Inc. is a global healthcare enterprise dedicated to the creation, production, and sale of a diverse array of pharmaceutical, medical device, and over-the-counter items. Its primary therapeutic focus areas include eye health, digestive system issues, and dermatological conditions. The company's operations are strategically organized into five key divisions: Bausch + Lomb, which specializes in vision care, surgical solutions, and ophthalmic pharmaceuticals; Salix, concentrating on gastroenterology products within the United States; International Rx, offering a broad portfolio encompassing Solta products, branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across numerous international markets in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East; Ortho Dermatologics, providing dermatological products in the U.S. and Solta medical aesthetic devices globally; and Diversified Products, covering pharmaceutical products in neurology and other therapeutic classes, alongside generic and dentistry items in the United States. Previously known as Valeant Pharmaceuticals International, Inc., the company adopted its current name in July 2018 and maintains its headquarters in Laval, Canada.
BHC Company Deck
BHC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong operational and financial execution with broad revenue and adjusted EBITDA growth across the company (notably Salix and Solta), improved margins, healthy cash flow and net debt reduction. Management reaffirmed guidance and highlighted strategic R&D progress (larsucosterol Phase III) and AI-driven commercial/R&D productivity gains. Offsetting risks include a decline in the Diversified segment, Canadian branded generic pressure, acquisition-related inventory costs at Solta, litigation-related cash outflows and policy/tariff and potential exclusivity risks for Xifaxan that could affect future cash flow. On balance, the positive operational momentum, sizable organic and reported growth, margin expansion and strong cash generation outweigh the headwinds described.View all BHC earnings summariesBHC Revenue Breakdown
47.34% Bausch + Lomb
25.69% Salix
12.23% International
10.77% Diversified Products
3.96% Solta Medical
BHC Stock 12 Month Forecast
Average Price Target
$7.67
▲(29.94% Upside)
Technical Analysis
Knight Therapeutics
―
Cipher Pharmaceuticals
―
Cronos Group
―
HLS Therapeutics Inc
―
DRI Healthcare
―
Ownership Overview
40.86% Insiders
2.90% Mutual Funds
39.55% Other Institutional Investors
10.77% Public Companies and
Individual Investors